CEF virus-specific Tetramers

The CEF peptide pool was initially described by Currier and include a well-defined set of 23 virus-derived peptides from Cytomegalovirus (C), Epstein Bar virus (E) and Influenza (Flu, F) viruses. The CEF peptide pool is extensively used as a positive control for CD8 T cell activation.

 

Peptides from the CEF pool causes CD8+ T cells to produce various cytokines including IFN-γ and is recommended as a positive control in IFN-γ ELISpot assays using human peripheral blood mononuclear cells (PBMC). The CEF pool has been shown to induce IFN-γ responses in up to 90% of all Caucasians.

 

CEF virus-specific CD8+T cells can be detected in preparations of lymphoid cells from infected individuals by staining with virus-specific Tetramers followed by flow cytometry analysis. Amongst the original 23 described virus peptides in the CEF pool are 4 peptide antigens frequently detected in humans using tetramer assays.

>> Order CEF virus-specific Tetramers to monitor CEF response

 

Cat. No.  HLA type  Pep. Seq.  Antigen
HA02-010 HLA-A*02:01 NLVPMVATV HCMV pp65 495-504
HA02-012 HLA-A*0201 GILGFVFTL Influenza A MP 58-66
HA02-011 HLA-A*0201 GLCTLVAML EBV BMLF-1 259-267
HB07-009 HLA-B*0702 RPPIFIRRL EBV EBNA-3A 247-255

>> Order negative control Tetramers

Cat. No. HLA type Pep. Seq. Antigen
HA02-025 HLA-A*0201 GVAGDVSAV Control
HA02-024 HLA-A*0201 AVIAPVHAV Control

>>Other virus-specific Tetramers not included in the CEF pool  

Cat. No. HLA type Pep. Seq. Antigen
HA02-028 HLA-A*02:01 VLEETSVML HCMV IE1 316-324 (UL123)
HB07-015 HLA-B*07:02 TPRVTGGGAM HCMV pp65 417-426
HB07-008 HLA-B*07:02 RPHERNGFTVL HCMV pp65 265-275
HA24-013 HLA-A*24:02 QYDPVAALF HCMV pp65 341-349
HA24-021 HLA-A*24:02 VYALPLKML HCMV pp65 113-121
HA02-016 HLA-A*02:01 CINGVCWTV HCV NS3 1073-1081
HA02-017 HLA-A*02:01 CLGGLLTMV EBV LMP-2 426-434
HA02-015 HLA-A*02:01 FLPSDFFPSV HBV Core antigen 18-27
HA02-026 HLA-A*02:01 FLYALALLL EBV LMP-2 356-364
HA02-018 HLA-A*02:01 ILKEPVHGV HIV-1 RT 476-484
HA02-013 HLA-A*02:01 LLMWEAVTV VP1 BK virus
HA02-014 HLA-A*02:01 SLYNTVATL HIV-1 gag p17 76-84
HA02-022 HLA-A*02:01 YMLDLQPET HPV 16 E7 11-19
HA02-027 HLA-A*02:01 YVLDHLIVV EBV BRLF1 109–117

 

Clinical relevance of CEF virus-specific Tetramers

More than 90% of the world population is or have been infected with CMV, EBV or influenza virus.

 

Virus infections and in particular latent virus represent a health risk for immunocompromised patients in lack of a sufficiently effective population of virus-specific T cells.

 

Patients in risk of virus outbreak include allogenic stem cell or organ transplant patients, AIDS/HIV patients, elderly or neonatal patients. Monitoring virus-specific CD8+ T cells can predict the immune status in immunocompromised individuals.  Virus-specific Tetramers can also be used for evaluating efficacy of virus-specific vaccines.

 

Advantages of virus-specific Tetramer assays.

Viral detection based on PCR and antigen-detection can examine viral burden and identify a reactivation of latent virus. However, these assays cannot assess the patients’ capability to respond to virus since these assays give no information regarding the existence of virus-specific T cells. CD8+ T cells are the main control against viral infection and adequate levels of virus-specific CD8 T cells are known to defend against viral disease.

 

Application of Tetramers

Tetramers are useful for detection, enumeration and isolation of virus-specific CD8+ T cells in a variety of Research Use Only (RUO) applications. Please check our standard protocols.

 

Tetramer specification

Tetramer Shop supply MHC Tetramers in various test sizes and the colors PE, BV421, BUV395, APC-Cy™7, APC, BV510, BV480, PE-Cy™5, PE-CF594, PE-Cy™7, PerCP-Cy™5.5, PerCP, FITC, BV605, BV650, BV786, APC-R700, BB515 and BUV737. For other colors, please enquire.